Download PDF
Der Nuklearmediziner 2011; 34(1): 45-53
DOI: 10.1055/s-0030-1270481
SPECT/CT

© Georg Thieme Verlag KG Stuttgart · New York

SPECT/CT bei differenziertem Schilddrüsenkarzinom

SPECT/CT in Differentiated Thyroid CarcinomaD. Schmidt1 , T. Kuwert1
  • 1Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum der Universität von Erlangen-Nürnberg, Erlangen
Further Information

Publication History

Publication Date:
23 March 2011 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die szintigrafische Bildgebung der Verteilung von Iodisotopen wird zum Staging von Patienten mit differenziertem Schilddrüsenkarzinom verwendet. Planare Szintigrafien mit einer Gammakamera sowie SPECT visualisieren iodakkumulierende Herde mit hoher Sensitivität. Allerdings ist die diagnostische Genauigkeit dieser Technik aufgrund des weitgehenden Fehlens morphologischer Informationen begrenzt. Diese Limitation lässt sich durch den Einsatz von Hybridsystemen bei denen eine SPECT Kamera und ein CT Scanner integriert sind umgehen. Aktuelle Studien haben gezeigt, dass ungefähr ein Drittel der Patienten mit einem diagnostisch unklaren Radioiod anreichernden Fokus vom Einsatz der SPECT/CT profitieren, auch im Bezug auf das therapeutische Management. Daher entwickelt sich die SPECT/CT zu einem neuen klinischen Verfahren bei differenziertem Schilddrüsenkarzinom.

Abstract

Scintigraphic imaging of the distribution of isotopes of radioiodine is frequently performed for staging patients with differentiated thyroid carcinoma. Planar gamma-camera imaging, as well as SPECT, visualize foci of radioiodine accumulation with high sensitivity. However, owing to only poor visualization of the morphology by these techniques, their diagnostic accuracy is limited. This limitation is overcome when hybrid systems integrating a SPECT camera with a x-ray CT scanner are used. Recent evidence has demonstrated that approximately a third of patients with diagnostically unclear foci of radioiodine accumulation will benefit from the use of SPECT/CT, also in terms of therapeutic management. Therefore, SPECT/CT is rapidly evolving as a new clinical tool in differentiated thyroid carcinoma.

Schlüsselwörter

SPECT/CT - Hybridbildgebung - Schilddrüsenkarzinom - Radioiod

Key words

SPECT/CT - hybrid imaging - thyroid carcinoma - radioiodine

Literatur

  • 1 Agriantonis DJ, Hall L, Wilson MA. Utility of SPECT/CT as an adjunct to planar whole body I-131 imaging: liver metastasis from papillary thyroid cancer.  Clin Nucl Med. 2009;  34 247-248
    CrossrefPubMedGoogle Scholar
  • 2 Aide N, Lehembre E, Gervais R. et al . Unusual intratracheal metastasis of differentiated thyroid cancer accurately depicted by SPECT/CT acquisition after radioiodine ablation.  Thyroid. 2007;  17 1305-1306
    CrossrefPubMedGoogle Scholar
  • 3 Aide N, Heutte N, Rame JP. et al . Clinical relevance of single-photon emission computed tomography/computed tomography of the neck and thorax in postablation (131)I scintigraphy for thyroid cancer.  J Clin Endocrinol Metab. 2009;  94 2075-2084
    CrossrefPubMedGoogle Scholar
  • 4 Bockisch A, Freudenberg LS, Schmidt D. et al . Hybrid imaging by SPECT/CT and PET/CT – proven outcomes in cancer imaging.  Semin Nucl Med. 2009;  39 276-289
    CrossrefPubMedGoogle Scholar
  • 5 Chen L, Luo Q, Shen Y. et al . Incremental value of 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma.  J Nucl Med. 2008;  49 1952-1957
    CrossrefPubMedGoogle Scholar
  • 6 Cooper DS, Doherty GM, Haugen BR. et al . Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.  Thyroid. 2009;  19 1167-1214
    Google Scholar
  • 7 Greene FL, Page DL, Fleming ID. et al .. (eds.) AJCC Cancer Staging Handbook. Springer, New York; 2002
    CrossrefGoogle Scholar
  • 8 Hay ID, McDougall IR, Sisson JC. A Proposition for the Use of Radioiodine in WDTC Management.  J Nucl Med. 2008;  49 1395-1397
    CrossrefPubMedGoogle Scholar
  • 9 Kohlfuerst S, Igerc I, Lobnig M. et al . Posttherapeutic 131I SPECT-CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen.  Eur J Nucl Med Mol Imaging. 2009;  36 886-893
    CrossrefPubMedGoogle Scholar
  • 10 Lind P, Kohlfürst S. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.  Semin Nucl Med. 2006;  36 194-205
    CrossrefPubMedGoogle Scholar
  • 11 Macdonald W, Armstrong J. Benign struma ovarii in a patient with invasive papillary thyroid cancer: detection with I-131 SPECT-CT.  Clin Nucl Med. 2007;  32 380-382
    CrossrefPubMedGoogle Scholar
  • 12 Mariani G, Bruselli L, Kuwert T. et al . A review on the clinical uses of SPECT/CT.  Eur J Nucl Med Mol Imaging. 2010;  37 1959-1985
    CrossrefPubMedGoogle Scholar
  • 13 Mustafa M, Kuwert T, Weber K. et al . Regional lymph node involvement in T1 papillary thyroid carcinoma: a bicentric prospective SPECT/CT study.  Eur J Nucl Med Mol Imaging. 2010;  37 1462-1466
    CrossrefPubMedGoogle Scholar
  • 14 Pacini F, Schlumberger M, Dralle H. et al The European Thyroid Cancer Taskforce European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.  Eur J Endocrinol. 2006;  154 787-803
    CrossrefPubMedGoogle Scholar
  • 15 Patton JA, Townsend DW, Hutton BF. Hybrid imaging technology: from dreams and vision to clinical devices.  Semin Nucl Med. 2009;  39 247-263
    CrossrefPubMedGoogle Scholar
  • 16 Qiu ZL, Luo QY. Erector spinae metastases from differentiated thyroid cancer identified by I-131 SPECT/CT.  Clin Nucl Med. 2009;  34 137-140
    CrossrefPubMedGoogle Scholar
  • 17 Rachinsky I, Driedger A. Iodine-131 uptake in a menstruating uterus: value of SPECT/CT in distinguishing benign and metastatic iodine-positive lesions.  Thyroid. 2007;  17 901-902
    CrossrefPubMedGoogle Scholar
  • 18 Ruf J, Lehmkuhl L, Bertram H. et al . Impact of SPECT and integrated low-dose CT after radioiodine therapy on the management of patients with thyroid carcinoma.  Nucl Med Commun. 2004;  25 1177-1182
    CrossrefPubMedGoogle Scholar
  • 19 Schlumberger M, Pacini F. Thyroid Tumors. Paris: Editions Nucléon; 2003
    Google Scholar
  • 20 Schmidt D, Szikszai A, Linke R. et al . Impact of 131I SPECT/Spiral CT on nodal staging of differentiated thyroid carcinoma at the first radioablation.  J Nucl Med. 2009;  50 18-23
    PubMedGoogle Scholar
  • 21 Schmidt D, Linke R, Uder M. et al . Five months’ follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by (131)I-SPECT/CT at the first radioablation.  Eur J Nucl Med Mol Imaging. 2010;  37 699-705
    CrossrefPubMedGoogle Scholar
  • 22 Shapiro B, Rufini V, Jarwan A. et al . Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole-body I-131 scans in patients with thyroid cancer.  Semin Nucl Med. 2000;  30 115-132
    CrossrefPubMedGoogle Scholar
  • 23 Sisson JC, Dewaraja YK, Wizauer EJ. et al . Thyroid carcinoma metastasis to skull with infringement of brain: treatment with radioiodine.  Thyroid. 2009 Mar;  19 297-303
    CrossrefPubMedGoogle Scholar
  • 24 Song H, He B, Prideaux A. et al . Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.  J Nucl Med. 2006;  47 1985-1994
    PubMedGoogle Scholar
  • 25 Spanu A, Solinas ME, Chessa F. et al . 131I SPECT/CT in the Follow-up of Differentiated Thyroid Carcinoma: Incremental Value Versus Planar Imaging.  J Nucl Med. 2009;  50 184-190
    CrossrefPubMedGoogle Scholar
  • 26 Tharp K, Israel O, Hausmann J. et al . Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma.  Eur J Nucl Med Mol Imaging. 2004;  31 1435-1442
    PubMedGoogle Scholar
  • 27 Thust S, Fernando R, Barwick T. et al . SPECT/CT identification of post-radioactive iodine treatment false-positive uptake in a simple renal cyst.  Thyroid. 2009;  19 75-76
    CrossrefPubMedGoogle Scholar
  • 28 Verburg FA, Dietlein M, Lassmann M. et al . Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma.  Eur J Nucl Med Mol Imaging. 2009;  36 343-346
    CrossrefPubMedGoogle Scholar
  • 29 von Falck C, Beer G, Gratz KF. et al . Renal metastases from follicular thyroid cancer on SPECT/CT.  Clin Nucl Med. 2007;  32 751-752
    CrossrefPubMedGoogle Scholar
  • 30 Wang H, Fu HL, Li JN. et al . The role of single-photon emission computed tomography/computed tomography for precise localization of metastases in patients with differentiated thyroid cancer.  Clin Imaging. 2009;  33 49-54
    CrossrefPubMedGoogle Scholar
  • 31 Wong KK, Zarzhevsky N, Cahill JM. et al . Incremental value of diagnostic 131I SPECT/CT fusion imaging in the evaluation of differentiated thyroid carcinoma.  AJR Am J Roentgenol. 2008;  191 1785-1794
    CrossrefPubMedGoogle Scholar
  • 32 Wong KK, Avram AM. Posttherapy I-131 thymic uptake demonstrated with SPECT/CT in a young girl with papillary thyroid carcinoma.  Thyroid. 2008;  18 919-920
    CrossrefPubMedGoogle Scholar
  • 33 Wong KK, Zarzhevsky N, Cahill JM. et al . Hybrid SPECT-CT and PET-CT imaging of differentiated thyroid carcinoma.  Br J Radiol. 2009;  82 860-876
    CrossrefPubMedGoogle Scholar
  • 34 Yamamoto Y, Nishiyama Y, Monden T. et al . Clinical usefulness of fusion of I-131 SPECT and CT images in patients with differentiated thyroid carcinoma.  J Nucl Med. 2003;  44 1905-1910
    PubMedGoogle Scholar

Korrespondenzadresse

Dr. Daniela Schmidt

Klinik für Nuklearmedizin

Universität Erlangen-Nürnberg

Krankenhausstraße 12

91054 Erlangen

Phone: +49/9131/853 3411

Fax: +49/9131/853 9262

Email: Daniela.Schmidt@uk-erlangen.de